论文部分内容阅读
目的观察沙利度胺对肝癌细胞HepG2化疗效果的影响。方法吉西他滨(0.30,1.25μg·mL-1)与沙利度胺(15.62μg·mL-1)联合处理HepG2肝癌细胞24 h,用MTT法测定细胞的增殖情况;Hoechst 33342染色检测细胞形态改变;用RT-PCR与免疫细胞化学法检测血管内皮细胞生长因子(VEGF)mRNA及蛋白表达。结果吉西他滨能浓度依赖性抑制HepG2细胞的增殖,而沙利度胺对其存活率影响不明显;与单用吉西他滨相比,两药联用对细胞增殖的抑制作用明显增加(P﹤0.05),且HepG2对吉西他滨敏感性的作用显著增加;两药联用可诱导HepG2细胞凋亡,导致HepG2细胞核形态改变更明显;与单用吉西他滨相比,两药联用后能明显下调VEGF在细胞的表达水平,且两药合用对VEGF表达的影响也有协同作用。结论沙利度胺可能通过下调VEGF表达以增加肝癌细胞HepG2对吉西他滨化疗的敏感性。
Objective To observe the effect of thalidomide on HepG2 cells. Methods HepG2 hepatocarcinoma cells were treated with gemcitabine (0.30,1.25μg · mL-1) and thalidomide (15.62μg · mL-1) for 24 hours. The proliferation of HepG2 cells was detected by MTT assay. The morphological changes were observed by Hoechst 33342 staining. The mRNA and protein expression of vascular endothelial growth factor (VEGF) were detected by RT-PCR and immunocytochemistry. Results Gemcitabine could inhibit the proliferation of HepG2 cells in a concentration-dependent manner, while thalidomide had no significant effect on the survival rate of HepG2 cells. Compared with gemcitabine alone, the combination of the two drugs inhibited the proliferation of HepG2 cells significantly (P <0.05) And the effect of HepG2 on gemcitabine sensitivity increased significantly; the combination of the two drugs can induce the apoptosis of HepG2 cells, resulting in more obvious morphological changes of HepG2 cells; compared with gemcitabine alone, the two drugs can significantly reduce the expression of VEGF in cells Level, and the combination of the two drugs have a synergistic effect on the expression of VEGF. Conclusions Thalidomide may increase the sensitivity of HepG2 cells to gemcitabine chemotherapy by downregulating VEGF expression.